Refine
Year of publication
Document Type
- Journal article (70)
- Conference Proceeding (8)
- Preprint (6)
- Doctoral Thesis (4)
Language
- English (88) (remove)
Keywords
- PET (21)
- Positronen-Emissions-Tomografie (20)
- positron emission tomography (20)
- PRRT (8)
- PET/CT (6)
- SPECT (6)
- neuroendocrine tumor (6)
- 18F-FDG (5)
- SSTR (5)
- prostate cancer (5)
- theranostics (5)
- CXCR4 (4)
- PSMA (4)
- RADS (4)
- lymphoma (4)
- 18F-DCFPyL (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- Parkinson’s disease (3)
- Prostate Cancer (3)
- ageing (3)
- chemokine receptor (3)
- dosimetry (3)
- molecular imaging (3)
- somatostatin receptor (3)
- vandetanib (3)
- 11C-HED (2)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 18F-FDS (2)
- 53BP1 (2)
- Biokinetics (2)
- Dosimetry (2)
- Ioflupane (2)
- Myokarditis (2)
- NET (2)
- Neuroendocrine Tumor (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- Positron emission tomography (2)
- Schilddrüsenkrebs (2)
- Stammzelle (2)
- TKI (2)
- Thyroid cancer (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- biokinetics (2)
- bone disease (2)
- cancer (2)
- cardiomyocytes (2)
- children (2)
- dopamine (2)
- fatty acid (2)
- follow-up (2)
- glioblastoma multiforme (2)
- heart (2)
- heart failure (2)
- hiPSC-CM (2)
- imaging (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- inflammation (2)
- involvement (2)
- magnetic resonance imaging (2)
- management (2)
- medullary thyroid carcinoma (2)
- multiple myeloma (2)
- myocardial sympathetic innervation imaging (2)
- myocarditis (2)
- peptide receptor radionuclide therapy (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- prognosis (2)
- prostate-specific membrane antigen (2)
- radioiodine therapy (2)
- radiotherapy (2)
- stem cell therapy (2)
- survival (2)
- thyroid cancer (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18-F-fluorothymidine uptake (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 1st International Workshop (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 5-Fluorouracil (1)
- 5IA-SPECT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 99mTc-DTPA (1)
- AI (1)
- Ablation <Medizin> (1)
- Absorbed Doses (1)
- Administered Activities (1)
- Antibodies (1)
- Antidepressants (1)
- Arginine (1)
- B-cell lymphoma (1)
- BRAF(V600E) mutation (1)
- C-11-methionine pet (1)
- CXCR4/SDF-1 (1)
- Central venous access (1)
- Chernobyl (1)
- DCGAN (1)
- DLBCL (1)
- DNA Breaks (1)
- DNA damage (1)
- DNA repair (1)
- DOPA-responsive-dystonia (1)
- DOTATOC (1)
- DWI (1)
- DYT1 (1)
- Diagnostic Imaging Exams (1)
- Diagnostic radiopharmaceuticals (1)
- Dystonia (1)
- ECG (1)
- Effective dose (1)
- Extraocular eye muscles (1)
- FDG (1)
- FDG PET/CT (1)
- FDG-PET (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- FLT-PET (1)
- FV45 (1)
- GAN (1)
- GCH1 (1)
- GI (1)
- Ga-68-labelled Peptides (1)
- Ganglia (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- Herz (1)
- Hickman catheter (1)
- Hodgkin-lymphoma (1)
- Hyperkalaemia (1)
- I-131 ablation (1)
- IBA-1 (1)
- ICD (1)
- Imaging pitfalls (1)
- JR11 (1)
- Knochendichte (1)
- Knochenstoffwechsel (1)
- Langfristige Prognose (1)
- Levothyroxine (1)
- Lysine (1)
- MAG3 (1)
- MDD (1)
- MI-RADS (1)
- MIBG (1)
- MPI (1)
- MRI (1)
- Magnetresonanztomografie (1)
- Medullärer Schilddrüsenkrebs (1)
- Merkel cell carcinoma (1)
- Metaiodobenzylguanidine (1)
- Metastases (1)
- Micronuclei (1)
- Molecular imaging (1)
- Muskelkraft (1)
- Myeloma cells (1)
- Myelomas (1)
- NVP-BGT226 (1)
- Neuroendocrine (1)
- Nierenfunktionsstörung (1)
- Nuclear Medicine (1)
- OPS201 (1)
- Oncology (1)
- P-glycoprotein expression (1)
- PROMISE (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pancreas (1)
- Parkinson disease (1)
- Parkinson's disease (1)
- Parkinsonism (1)
- Pediatric Nuclear Medicine (1)
- Pediatric Patients (1)
- Pediatric malignancy (1)
- Pitfall (1)
- Port (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- Ra-224 (1)
- Radiation Protection (1)
- Radiation-associated Cancer Risk (1)
- Radioiod (1)
- Radioiodine (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- Radium (1)
- Rhabdomyosarcoma (1)
- Risk Assessment (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SSTR-RADS (1)
- Schilddrüse (1)
- Schilddrüsenhormontherapie (1)
- Simvastatin (1)
- Single-Photon-Emissions-Computertomographie (1)
- Somatostatin receptor expression (1)
- Standardisierung (1)
- T-Lymphozyten-Rezeptor (1)
- T-cell receptor assay (1)
- TBI (1)
- TSPO (1)
- Tc-99m-MAG3 Scans (1)
- Technetium Tc 99m Sestamibi Rats (1)
- Thrombosis (1)
- Thyroid carcinoma (1)
- Tracer (1)
- Transferrin-positive reticulocytes (1)
- WB-DW-MRI (1)
- ZDF rats (1)
- [18F]Fluorodeoxythymidine (1)
- [68Ga]DOTATOC (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{177}\)Lu-OPS201 (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga-Pentixafor (1)
- \(^{99m}\)Tc-MAG3 (1)
- absorbed dose (1)
- absorbed dose to the blood (1)
- acute myeloid leukemia (1)
- adrenocortical (1)
- advanced stages (1)
- alpha particles (1)
- alpha-emitters (1)
- amino acids (1)
- analysis (1)
- angiotensin II type 1 receptor (1)
- antagonist (1)
- antidepressant (1)
- antidepressants (1)
- areas (1)
- arrhythmia (1)
- artificial intelligence (1)
- association (1)
- autologous transplantation (1)
- autonomic nervous system (1)
- autoradiography (1)
- beta oscillations (1)
- biological dosimetry (1)
- biosynthesis (1)
- blood (1)
- bone marrow cells (1)
- bone metabolism (1)
- bone mineral density (1)
- bone-targeting radiopharmaceuticals (1)
- brain tumors (1)
- calcitonin (1)
- cancer treatment (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac (1)
- cardiac innervation imaging (1)
- cardiac nerve (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cell staining (1)
- cells (1)
- cerebral gliomas (1)
- chemokine receptor-4 (1)
- cholinergic activity (1)
- chromatin mobility (1)
- coefficient (1)
- cognitive decline (1)
- coherence analysis (1)
- coronary artery disease (1)
- damage (1)
- delineation (1)
- depression (1)
- diabetes (1)
- diabetic cardiomyopathy (1)
- diffuse (1)
- diffusion weighted MRI (1)
- dissection (1)
- distant metastases (1)
- dopamine acetylcholine (1)
- dose response (1)
- double-stranded (1)
- early response (1)
- endocrinology (1)
- esophagogastric junction (1)
- exome sequencing (1)
- experience (1)
- exposure (1)
- focal (1)
- folinic acid (1)
- follicular lymphoma (1)
- gamma rays (1)
- gemcitabine (1)
- glioblastoma (1)
- glioma (1)
- guidelines (1)
- health care (1)
- healthy volunteers (1)
- heart failure with mid-range ejection fraction (1)
- heptacellular carcinoma (1)
- histone H2AX (1)
- humans (1)
- hydroxyephedrine (1)
- hyperkalemia (1)
- imaging proliferation (1)
- imaging techniques (1)
- immunohistochemistry (1)
- immunostaining (1)
- improves (1)
- in vivo formation (1)
- in-vivo (1)
- inhibition (1)
- initial experience (1)
- interobserver (1)
- interreader (1)
- iodine nutrition (1)
- irinotecan (1)
- isotopes (1)
- kidney (1)
- kidney function (1)
- kinase inhibitor (1)
- lesions (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- locally advanced disease (1)
- lutetium-177 (1)
- mIBG (1)
- machine learning (1)
- macrophages (1)
- major depressive disorder (1)
- malignancies (1)
- malignant lymphoma (1)
- mammalian target of rapamycin (1)
- mechanisms retention (1)
- medicine (1)
- medullary thyroid cancer (1)
- methionine pet (1)
- microenvironment (1)
- microglial cells (1)
- molecular medicine (1)
- motor control (1)
- movement disorders (1)
- moycardial sympathetic innervation (1)
- muscle force (1)
- myocardial nerve (1)
- myocardial perfusion imaging (1)
- nab-paclitaxel (1)
- neoadjuvant chemotherapy (1)
- neuroendocrine neoplasia (1)
- neuroendocrine tumor (NET) (1)
- neuroendocrine tumors (1)
- neuroinflammation (1)
- nicotinic receptors (1)
- non-Hodgkin's lymphoma (1)
- non-hodgkins-lymphoma (1)
- nuclear cardiology (1)
- osteoporosis (1)
- oxaliplatin (1)
- pancreas (1)
- pancreatic cancer (1)
- papillary (1)
- pediatric patients (1)
- peptide receptor (1)
- peripheral injury (1)
- phaeochromocytoma (1)
- phosphatidylinositol-3-kinase (1)
- phosphorylation (1)
- photons (1)
- pig model (1)
- pleural mesothelioma (1)
- pooled (1)
- positron emission tomography/computed tomography (1)
- positron-emission-tomography (1)
- power-station accident (1)
- prognostic value (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- radiation (1)
- radiation effects (1)
- radionuclide therapy (1)
- radiotracer (1)
- radium (1)
- recurrence (1)
- renal failure (1)
- renal imaging (1)
- renin-angiotensin system (1)
- repair (1)
- reporting and data system (1)
- reporting and data systems (1)
- response evaluation (1)
- risk (1)
- risk assessment (1)
- salvage radiotherapy (1)
- sarcoidosis (1)
- second hit (1)
- sepsis (1)
- signal to noise ratio (1)
- signaling pathway (1)
- single photon emission computed tomography: sympathetic nerve (1)
- skin hemagioma (1)
- somatostatin (1)
- somatostatin receptor (SSTR) (1)
- somatostatin receptors (1)
- split renal function (1)
- standardization (1)
- standardized reporting (1)
- stem-cell transplantation (1)
- storage vesicle turnover (1)
- stroke (1)
- subthalamic nucleus (1)
- super ultraviolet (1)
- surgery (1)
- surgical treatment (1)
- sympathetic nerve (1)
- sympathetic nervous system (1)
- target (1)
- therapeutic target (1)
- thyroid carcinomas (1)
- treatment (1)
- treatment response (1)
- trial (1)
- tumor (1)
- unilateral ureteral obstruction (1)
- valsartan (1)
- weight drop (1)
- whole body MRI (1)
- whole-body (1)
- α-emitter (1)
- γ-H2AX (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (88) (remove)
DNA double strand break (DSB) formation induced by ionizing radiation exposure is indicated by the DSB biomarkers \(\gamma\)-H2AX and 53BP1. Knowledge about DSB foci formation in-vitro after internal irradiation of whole blood samples with radionuclides in solution will help us to gain detailed insights about dose-response relationships in patients after molecular radiotherapy (MRT). Therefore, we studied the induction of radiation-induced co-localizing \(\gamma\)-H2AX and 53BP1 foci as surrogate markers for DSBs in-vitro, and correlated the obtained foci per cell values with the in-vitro absorbed doses to the blood for the two most frequently used radionuclides in MRT (I-131 and Lu-177). This approach led to an in-vitro calibration curve. Overall, 55 blood samples of three healthy volunteers were analyzed. For each experiment several vials containing a mixture of whole blood and radioactive solutions with different concentrations of isotonic NaCl-diluted radionuclides with known activities were prepared. Leukocytes were recovered by density centrifugation after incubation and constant blending for 1 h at 37°C. After ethanol fixation they were subjected to two-color immunofluorescence staining and the average frequencies of the co-localizing \(\gamma\)-H2AX and 53BP1 foci/nucleus were determined using a fluorescence microscope equipped with a red/green double band pass filter. The exact activity was determined in parallel in each blood sample by calibrated germanium detector measurements. The absorbed dose rates to the blood per nuclear disintegrations occurring in 1 ml of blood were calculated for both isotopes by a Monte Carlo simulation. The measured blood doses in our samples ranged from 6 to 95 mGy. A linear relationship was found between the number of DSB-marking foci/nucleus and the absorbed dose to the blood for both radionuclides studied. There were only minor nuclide-specific intra-and inter-subject deviations.
Objective: To investigate the association between levodopa‐induced dyskinesias and striatal cholinergic activity in patients with Parkinson's disease.
Methods: This study included 13 Parkinson's disease patients with peak‐of‐dose levodopa‐induced dyskinesias, 12 nondyskinetic patients, and 12 healthy controls. Participants underwent 5‐[\(^{123}\)I]iodo‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine single‐photon emission computed tomography, a marker of nicotinic acetylcholine receptors, [\(^{123}\)I]N‐ω‐fluoropropyl‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)nortropane single‐photon emission computed tomography, to measure dopamine reuptake transporter density and 2‐[\(^{18}\)F]fluoro‐2‐deoxyglucose positron emission tomography to assess regional cerebral metabolic activity. Striatal binding potentials, uptake values at basal ganglia structures, and correlations with clinical variables were analyzed.
Results: Density of nicotinic acetylcholine receptors in the caudate nucleus of dyskinetic subjects was similar to that of healthy controls and significantly higher to that of nondyskinetic patients, in particular, contralaterally to the clinically most affected side.
Interpretation: Our findings support the hypothesis that the expression of dyskinesia may be related to cholinergic neuronal excitability in a dopaminergic‐depleted striatum. Cholinergic signaling would play a role in maintaining striatal dopaminergic responsiveness, possibly defining disease phenotype and progression.
The risk of developing thyroid cancer increases considerably after exposure to external or internal radiation, especially in children below the age of 10. After the Chernobyl reactor accident, the yearly incidence of childhood thyroid cancer in Belarus increased to approximately 40 per 1.000.000 in girls and to roughly 20 per 1.000.000 in boys compared to approximately 0.5 cases per 1.000.000 prior to the accident. Typically, young children with thyroid cancer after radiation exposure present in ≈95% of the cases as papillary cancers, in ≈50% as invasive tumors growing outside the thyroid capsule, in ≈65% with lymph node metastases and in ≈15% with distant metastases. A joint Belarusian-German project starting in April 1993 that combined treatment with surgery and radioiodine was organized in 237 selected children from Belarus who were exposed to the Chernobyl fallout and had advanced stages of thyroid cancer. The study group included 141 girls and 96 boys. Their median age at the time of the accident was 1.7 years; whereas the median age at the time of diagnosis was 12.4 years. With the exception of two cases with follicular histology, the majority of the patients had been diagnosed with papillary thyroid cancers. In 63%, the tumor had grown outside the thyroid capsule and invaded the tissue of the neck (pT4). Nearly all of the selected cases (96%) showed-up with lymph node metastases (pN1) and 43% of the patients with distant metastases mainly to the lungs (pM1). In 58% of the children, complete remissions of thyroid cancer could be achieved until December 31st 2010 and in 34% of the children, stable partial remissions; in the remaining 8% of the patients, partial remissions were observed. The risk of radiation-induced thyroid cancer increased considerably in children and adolescents who were affected by the Chernobyl reactor accident. In spite of the fact, that thyroid cancers in young children seem to behave more aggressively than in older patients, the results of combined treatment with thyroidectomy, radioiodine therapy and thyroid hormone replacement are excellent.
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer. Different radionuclides that emit β-rays such as 153Samarium and 89Strontium and achieve palliation are commercially available. In contrast to β-emitters, 223Radium as a α-emitter has a short path-length. The advantage of the α-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms. Due to the limited range of the α-particles the bone surface to red bone marrow dose ratio is also lower for 223Radium which is expressed in a lower myelotoxicity. The α emitter 223Radium dichloride is the first radiopharmaceutical that significantly prolongs life in castrate resistant prostate cancer patients with wide-spread bone metastatic disease. In a phase III, randomized, double-blind, placebo-controlled study 921 patients with castration-resistant prostate cancer and bone metastases were randomly assigned. The analysis confirmed the 223Radium survival benefit compared to the placebo (median, 14.9 mo vs 11.3 mo; P < 0.001). In addition, the treatment results in pain palliation and thus, improved quality of life and a delay of skeletal related events. At the same time the toxicity profile of 223Radium was favourable. Since May 2013, 223Radium dichloride (Xofigo®) is approved by the US Food and Drug Administration.
Core tip: The incidence rate of prostate cancer worldwide is high. Ninety percent of patients dying of prostate cancer have bone metastases with varying symptoms which are significantly impairing their quality of life. 223Radium is the first therapeutic that results in a survival benefit for patients with bone metastatic, castrate resistant prostate cancer. 223Radium was also associated with low myelosuppression rates and fewer adverse events.This article provides an overview of the pre-clinical and clinical trials with 223Radium.
Background
Traumatic brain injury (TBI) is a major cause of death and disability. Neuroinflammation contributes to acute damage after TBI and modulates long-term evolution of degenerative and regenerative responses to injury. The aim of the present study was to evaluate the relationship of microglia activation to trauma severity, brain energy metabolism, and cellular reactions to injury in a mouse closed head injury model using combined in vivo PET imaging, ex vivo autoradiography, and immunohistochemistry.
Methods
A weight-drop closed head injury model was used to produce a mixed diffuse and focal TBI or a purely diffuse mild TBI (mTBI) in C57BL6 mice. Lesion severity was determined by evaluating histological damage and functional outcome using a standardized neuroscore (NSS), gliosis, and axonal injury by immunohistochemistry. Repeated intra-individual in vivo μPET imaging with the specific 18-kDa translocator protein (TSPO) radioligand [\(^{18}\)F]DPA-714 was performed on day 1, 7, and 16 and [\(^{18}\)F]FDG-μPET imaging for energy metabolism on days 2–5 after trauma using freshly synthesized radiotracers. Immediately after [\(^{18}\)F]DPA-714-μPET imaging on days 7 and 16, cellular identity of the [\(^{18}\)F]DPA-714 uptake was confirmed by exposing freshly cut cryosections to film autoradiography and successive immunostaining with antibodies against the microglia/macrophage marker IBA-1.
Results
Functional outcome correlated with focal brain lesions, gliosis, and axonal injury. [\(^{18}\)F]DPA-714-μPET showed increased radiotracer uptake in focal brain lesions on days 7 and 16 after TBI and correlated with reduced cerebral [\(^{18}\)F]FDG uptake on days 2–5, with functional outcome and number of IBA-1 positive cells on day 7. In autoradiography, [\(^{18}\)F]DPA-714 uptake co-localized with areas of IBA1-positive staining and correlated strongly with both NSS and the number of IBA1-positive cells, gliosis, and axonal injury. After mTBI, numbers of IBA-1 positive cells with microglial morphology increased in both brain hemispheres; however, uptake of [\(^{18}\)F]DPA-714 was not increased in autoradiography or in μPET imaging.
Conclusions
[\(^{18}\)F]DPA-714 uptake in μPET/autoradiography correlates with trauma severity, brain metabolic deficits, and microglia activation after closed head TBI.
Background:
Irradiation with α-particles creates densely packed damage tracks along particle trajectories in exposed cells, including complex DNA damage and closely spaced double-strand breaks (DSBs) in hit nuclei. Here, we investigated the correlation of the absorbed dose to the blood and the number of α-induced DNA damage tracks elicited in human blood leukocytes after ex-vivo in-solution exposure with Ra-224. The aim was to compare the data to previously published data on Ra-223 and to investigate differences in DNA damage induction between the two radium isotopes.
Results:
Blood samples from three healthy volunteers were exposed ex-vivo to six different concentrations of Ra-224 dichloride. Absorbed doses to the blood were calculated assuming local energy deposition of all α- and β-particles of the Ra-224 decay chain, ranging from 0 to 127 mGy. γ-H2AX + 53BP1 DNA damage co-staining and analysis was performed on ethanol-fixed leukocytes isolated from the irradiated blood samples. For damage quantification, α-induced DNA damage tracks and small γ-H2AX + 53BP1 DSB foci were enumerated in the exposed leukocytes. This revealed a linear relationship between the frequency of α-induced γ-H2AX damage tracks and the absorbed dose to the blood, while the frequency of small γ-H2AX + 53BP1 DSB foci indicative of β-irradiation was similar to baseline values.
Conclusions:
Our data provide a first estimation of the DNA damage induced by Ra-224 in peripheral blood mononuclear cells. A comparison with our previously published Ra-223 data suggests that there is no difference in the induction of radiation-induced DNA damage between the two radium isotopes due to their similar decay properties.
Background: Use of FDG-PET/CT for staging and restaging of lymphoma patients is widely incorporated into current practice guidelines. Our aim was to prospectively evaluate the diagnostic performance of FDG-PET/MRI and WB-DW-MRI compared with FDG-FDG-PET/CT using a tri-modality PET/CT-MRI system.
Methods: From 04/12 to 01/14, a total of 82 FDG-PET/CT examinations including an additional scientific MRI on a tri-modality setup were performed in 61 patients. FDG-PET/CT, FDG-PET/MRI, and WB-DW-MRI were independently analyzed. A lesion with a mean ADC below a threshold of 1.2 x 10\(^{-3}\) mm\(^2\)/s was defined as positive for restricted diffusion. FDG-PET/CT and FDG-PET/MRI were evaluated for the detection of lesions corresponding to lymphoma manifestations according to the German Hodgkin Study Group. Imaging findings were validated by biopsy (n = 21), by follow-up imaging comprising CT, FDG-PET/CT, and/or FDG-PET/MRI (n = 32), or clinically (n = 25) (mean follow-up: 9.1 months).
Results: FDG-PET/MRI and FDG-PET/CT accurately detected 188 lesions in 27 patients. Another 54 examinations in 35 patients were negative. WB-DW-MRI detected 524 lesions, of which 125 (66.5 % of the aforementioned 188 lesions) were true positive. Among the 188 lesions positive for lymphoma, FDG-PET/MRI detected all 170 instances of nodal disease and also all 18 extranodal lymphoma manifestations; by comparison, WB-DW-MRI characterized 115 (67.6 %) and 10 (55.6 %) lesions as positive for nodal and extranodal disease, respectively. FDG-PET/MRI was superior to WB-DW-MRI in detecting lymphoma manifestations in patients included for staging (113 vs. 73), for restaging (75 vs. 52), for evaluation of high-(127 vs. 81) and low-grade lymphomas (61 vs. 46), and for definition of Ann Arbor stage (WB-DW-MRI resulted in upstaging in 60 cases, including 45 patients free of disease, and downstaging in 4).
Conclusion: Our results indicate that FDG-PET/CT and FDG-PET/MRI probably have a similar performance in the clinical work-up of lymphomas. The performance of WB-DW-MRI was generally inferior to that of both FDG-PET-based methods but the technique might be used in specific scenarios, e.g., in low-grade lymphomas and during surveillance.
Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
(2015)
Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
DNA damage in leukocytes after internal ex-vivo irradiation of blood with the α-emitter Ra-223
(2018)
Irradiation with high linear energy transfer α-emitters, like the clinically used Ra-223 dichloride, severely damages cells and induces complex DNA damage including closely spaced double-strand breaks (DSBs). As the hematopoietic system is an organ-at-risk for the treatment, knowledge about Ra-223-induced DNA damage in blood leukocytes is highly desirable. Therefore, 36 blood samples from six healthy volunteers were exposed ex-vivo (in solution) to different concentrations of Ra-223. Absorbed doses to the blood were calculated assuming local energy deposition of all α- and β-particles of the decay, ranging from 0 to 142 mGy. γ-H2AX + 53BP1 co-staining and analysis was performed in leukocytes isolated from the irradiated blood samples. For DNA damage quantification, leukocyte samples were screened for occurrence of α-induced DNA damage tracks and small γ-H2AX + 53BP1 DSB foci. This revealed a linear relationship between the frequency of α-induced γ-H2AX damage tracks and the absorbed dose to the blood, while the frequency of small γ-H2AX + 53BP1 DSB foci indicative of β-irradiation was similar to baseline values, being in agreement with a negligible β-contribution (3.7%) to the total absorbed dose to the blood. Our calibration curve will contribute to the biodosimetry of Ra-223-treated patients and early after incorporation of α-emitters.